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Abstract
We have reviewed the impact of the ubiquitin proteasome system (UPS) on atherosclerosis
progression of diabetic patients. A puzzle of many pieces of evidence suggests that UPS, in addition
to its role in the removal of damaged proteins, is involved in a number of biological processes
including inflammation, proliferation and apoptosis, all of which constitute important characteristics
of atherosclerosis. From what can be gathered from the very few studies on the UPS in diabetic
cardiovascular diseases published so far, the system seems to be functionally active to a different
extent in the initiation, progression, and complication stage of atherosclerosis in the diabetic
people. Further evidence for this theory, however, has to be given, for instance by specifically
targeted antagonism of the UPS. Nonetheless, this hypothesis may help us understand why diverse
therapeutic interventions, which have in common the ability to reduce ubiquitin-proteasome
activity, can impede or delay the onset of diabetes and cardiovascular diseases (CVD).
People with type 2 diabetes are disproportionately affected by CVD, compared with those without
diabetes [1]. The prevalence, incidence, and mortality from all forms of CVD (myocardial infarction,
cerebro-vascular disease and congestive heart failure) are strikingly increased in persons with
diabetes compared with those withoutdiabetes [2]. Furthermore, diabetic patients have not
benefited by the advances in the management of obesity, dyslipidemia, and hypertension that have
resulted in a decrease in mortality for coronary heart disease (CHD) patients without diabetes [3].
Nevertheless, these risk factors do not fully explain the excess risk for CHD associated with
diabetes [4,5]. Thus, the determinants of progression of atherosclerosis in persons with diabetes
must be elucidated. Beyond the major risk factors, several studies have demonstrated that such
factors, strictly related to diabetes, as insulin-resistance, post-prandial hyperglycemia and chronic
hyperglycemia play a role in the atherosclerotic process and may require intervention [6,7].
Moreover, it is important to recognize that these risk factors frequently "cluster" inindividual
patients and possibly interact with each other, favouring the atherosclerosis progression toward
plaque instability. Thus, a fundamental question is, "which is the common soil hypothesis that may
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unifying the burden of all these factors on atherosclerosis of diabetic patients? Because evidences
suggest that insulin-resistance, diabetes and CHD share in common a deregulation of ubiquitin-
proteasome system (UPS), the major pathway for nonlysosomal intracellular protein degradation
in eucaryotic cells [8,9], in this review ubiquitin-proteasome deregulation is proposed as the
common persistent pathogenic factor mediating the initial stage of the atherosclerosis as well as
the progression to complicated plaque in diabetic patients.
Ubiquitin proteasome dysfunction in 
atherosclerosis process
Ciechanover [10] presented in 1978 the first description
of a heat-stable polypeptide that associated with an ATP-
dependent proteolytic system in reticulocytes that had
been previously described by Etlinger [11] in 1977. This
proteolytic complex has been known by several names,
including macroxyproteinase, multicatalytic proteinase
complex, prosome, and, most commonly, the proteasome
[12]. The UPS is responsible for the non-lysosomal degra-
dation of the majority of intracellular proteins [13] thus
playing a crucial role in the regulation of many cellular
processes. The process of ubiquitination requires various
enzymatic activity, involving specific proteins (i.e. E1, E2,
E3) which activate and transfer polyubiquitin chains to
target proteins, leading eventually to the formation of a
complex which is recognized and degraded by the 26S
proteasome complex [13]. This complex is composed of a
20S core particle which embodies the catalytic activity and
two 19S regulatory particles. The targets of the UPS
include key regulators of cell cycle and apoptosis and var-
ious transcription factors, whose intracellular levels are
finely tuned in the maintenance of the optimum equilib-
rium for cell division, growth, differentiation, signal trans-
duction and response to stress [14]. In addition, the UPS
plays key roles in protein quality by removal of damaged,
oxidized, and/or misfolded proteins [14] (Figure 1). Many
of these processes are crucially involved in the onset, pro-
gression, and complication of atherosclerosis. In particu-
lar the UPS may be influenced by oxidative stress and
plays a key role in the activation of nuclear factor kappa B
(NFkB) [15], which has been associated with coronary
[16] and carotid [17] plaque instability. Previous studies,
however, indicated that the UPS could be functionally
impaired under conditions of increased endogenous oxi-
dative stress, such as diabetes and coronary artery disease
[18]. Of note, it has been shown that oxidative stress can
stimulate the UPS in macrophages by inducing the expres-
sion of components of its enzymatic machinery such as
ubiquitin-binding proteins [19,20]. Accordingly, in cul-
tured monocytes from patients with cerebrovascular dis-
ease has been evidenced that superoxide anion
production as well as ubiquitin-proteasome activity and
NFkB levels were significantly higher when compared to
patients without cerebrovascular disease [21]. NFkB is
normally bound to IkB in the cytosol; this binding pre-
vents its movement into the nucleus [21]. Oxidative stress
may induce ubiquitination of phosphorylated IkBs and
subsequent degradation by the proteasome [22]. Degra-
dation of IkBs results in unmasking of the nuclear locali-
zation signal of NFkB dimers, which subsequently
translocates to the nucleus, where it induces the transcrip-
tion of proinflammatory cytokines that play a central role
in plaque instability progression [23]. Thus, increased
ubiquitin-proteasome activity in plaque macrophage as
consequence of oxidative stress overexpression may
enhance the synthesis of NFkB in the same cell, possibly
representing a crucial step in the pathophysiology of
atherosclerosis progression. Foremost, a vicious circle can
Illustration of the basic set of reactions in protein modifica- tion by ubiquitin Figure 1
Illustration of the basic set of reactions in protein modifica-
tion by ubiquitin. Processing of precursor molecules is neces-
sary for the exposure of the conjugation site in most cases. 
Following its activation by the action of an E1 enzyme, the 
mature molecule is transferred to an E2 enzyme, which cata-
lyzes the conjugation to the target protein. The latter action 
may require another "ligating" E3 enzyme. This conjugation 
process is balanced by deconjugation, which is mediated by a 
number of different enzymes. Degradation occurs in the 26S 
core proteasome, which contains multiple proteolytic sites 
within its two central rings. Peptides produced by the pro-
teasome are released and rapidly degraded to amino acids by 
peptidases in the cytoplasm or transported to the endoplas-
mic reticulum and used in the presentation of class I antigens. 
The ubiquitin is not degraded but is released and reused.Cardiovascular Diabetology 2007, 6:35 http://www.cardiab.com/content/6/1/35
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also develop: increased ubiquitin-proteasome activity in
atherosclerotic vessels leads to increased inflammatory
activity, which in turn leads to further increments of oxi-
dative stress and consequently may increase the ubiquiti-
nated proteins. Thus, these biological pathways including
inflammation, cell proliferation, and oxidative stress, sup-
port a potential involvement of the UPS in the initiation,
progression, and complication stage of atherogenesis [9]
(Figure 2).
Insulin-resistance effects on vascular biology: 
role of UPS activity
During the initial insulin-resistant period, or "prediabe-
tes," the metabolic and physiological changes proceed in
parallel with the commencement of silent atherosclerosis
and cardiovascular complications in genetically suscepti-
ble people, before the onset of diabetes. The spectrum of
atherosclerotic disturbances associated with insulin-resist-
ance extends beyond hyperglycemia, dyslipidemia, and
inflammation. Indeed, insulin receptor signalling deregu-
lation seems to play a crucial role in causing atherosclero-
sis related to insulin-resistance. Binding of insulin to its
receptor stimulates phosphorylation of a set of 'insulin
receptor substrate' proteins, which in turn recruit and acti-
vate a lipid kinase, phosphatidylinositol 3-kinase (PI3K)
[24]. Insulin, a vasodilator, increases endothelial nitric
oxide (NO) production and is regulated via PI3K-depend-
ent/Akt insulin receptor signaling [25]. In insulin-resist-
ance, the suppression of PI3K/Akt signaling reduces NO
production and impacts not only on endothelial cells but
also on VSMCs, resulting in increased contraction [26].
Endothelial dysfunction is one of the earliest detectable
signs in insulin-resistance, occurring even before the
development of clinical manifestations. Recent reports
have demonstrated that members of the ubiquitin-protea-
some pathway represent new partners that have to be
taken into account for the regulation of insulin action.
The protein amounts of the different signaling molecules
involved in insulin action are regulated by their rates of
synthesis and degradation. The UPS is involved in the
internalization of the insulin receptor, in the control of
the amount of insulin receptor substrates 1 and 2 (IRS-1,
IRS-2), and in insulin degradation [27]. Interestingly,
TNF-α seems to be responsible for the insulin-resistance
associated with obesity, since decreases the tyrosine
kinase activity of the insulin receptor [28]. It has been
demonstrated that TNF-α is able to activate the proteas-
ome-mediated ubiquitin-dependent proteolysis. Since
this proteolytic system is involved in the control of recep-
tor-associated (tyrosine-kinase activity insulin receptor),
it is postulated here that the mechanism of TNF-α-
induced insulin-resistance is mediated by the activation of
the UPS-dependent proteolysis [29]. Therefore, it appears
that altered UPS might be one of the molecular mecha-
nisms of insulin-resistance. In this scenario, insulin-resist-
ance may causes suppression of PI3K/Akt signaling
leading to activation of ubiquitin-proteasome proteolytic
pathway [30]. Moreover, the proteasome inhibitor,
PS341, could increase the level of PI3K and inhibit the
downstream pathway of PI3K-dependent/Akt insulin
receptor signaling, interfering with phosphorylation of
Akt [31]. Thus, insulin-resistance in vascular tissue causes
down-regulation of the PI3K pathway with consequential
reduction of the antiatherogenic effects, interestingly this
process may be influenced by UPS activity (Figure 3).
Postprandial hyperglycemia effects on 
endothelial dysfunction: role of UPS activity
Repeated exposure to hyperglycemia can lead to endothe-
lial pathology that may become irreversible over time
[32]. Russell Ross [33] is highly regarded for his enuncia-
tion of the response-to-injury hypothesis, which states
that endothelial damage precedes SMC migration and
proliferation, deposition of intracellular and extracellular
lipid, and accumulation of extracellular matrix. Subse-
quently, the response-to-injury hypothesis was broadened
to include endothelial dysfunction and endothelial activa-
tion as the key events that precede endothelial damage
In this model, atherosclerosis process results from patho- physiological activity of UPS that may activate the NFkB  inflammatory activity in the plaque macrophages Figure 2
In this model, atherosclerosis process results from patho-
physiological activity of UPS that may activate the NFkB 
inflammatory activity in the plaque macrophages. Activation 
pathway of NFkB, a homo- or heterodimeric transcription 
factor, composed by members of the Rel family of proteins. 
The classical example of NFkB is the heterodimer of p50 and 
p65, which binds to the 5'-GGGANNYYCCC-3' consensus 
sequence, once released from the association with an inhibi-
tory molecule of the IkB family, primarily IkBα and IkBβ. 
Upon exposure of the cell to various stimuli such as increase 
in oxidative stress, two specific serine residues are rapidly 
phosphorylated by the IKK1/2 kinases. Once phosphorylated, 
IkBs undergo degradation via the ubiquitin-proteasome path-
way in this main route of NFkB activation.Cardiovascular Diabetology 2007, 6:35 http://www.cardiab.com/content/6/1/35
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and initiate the inflammatory mechanisms associated
with atherosclerosis [34]. It has been demonstrated that
hyperglycemic spikes induce, in both diabetic and normal
subjects, an endothelial dysfunction [35,36]. Hyperglyc-
emia may reduce both the bioavailability and the produc-
tion of NO. Recent studies demonstrate that
hyperglycemia induces an overproduction of superoxide
by the mitochondrial electron-transport chain [37].
Superoxide overproduction is accompanied by increased
NO generation, due to both endothelial NO synthase
(eNOS) and inducible NO synthase (iNOS) [38]. Thesi-
multaneous overgeneration of NO and superoxide favors
theproduction of a toxic reaction product, the peroxyni-
trite anion [39]. This reaction may evoke endothelial dys-
function both reducing NO availability and producing
peroxynitrite anion. Moreover, the peroxynitrite anion is
cytotoxic because it oxidizes sulfydryl groups in protein-
sand nitrates amino acids such as tyrosine (nitrotyrosine),
which results in acute endothelial dysfunction, due to the
reduced NO availability [40,41]. However, recent data
demonstrated that hyperglycemia reduces levels of tet-
rahydrobiopterin (BH4), an essential cofactor for eNOS,
via 26S proteasome-mediated degradation of guanosine
5'-triphosphate cyclohydrolase I (GTPCH), which is the
rate-limiting enzyme of BH4 synthesis [42]. Additionally,
the authors found that hyperglycemia significantly
increased superoxide anion and 3-nitrotyrosine-positive
proteins and that adenoviral overexpression of superoxide
dismutase (SOD) significantly attenuated hyperglycemia-
induced 26S proteasome activation and GTPCH reduc-
tion. Thus, it is likely that the hyperglycemia-induced pro-
teasome activation and GTPCH reduction are mediated by
endogenous peroxynitrite anion. Moreover, administra-
tion of either the proteasome inhibitor MG132 or the
SOD mimetic tempol reversed the reduction of both
GTPCH and BH4 in STZ-induced diabetes mellitus in
mice. Finally, MG132 abolished diabetes mellitus-
induced endothelial dysfunction in vivo. Therefore, BH4
deficiency in diabetes mellitus is due to a reduction in
GTPCH, an enzyme critical to BH4 synthesis, via a process
that is peroxynitrite mediated and proteasome dependent.
These results may have uncovered a novel mechanism
underlying endothelial dysfunction in diabetic vascular
diseases. On the other hand, hyperglycemic spikes may
also evoked endothelial dysfunction reducing NO pro-
duction through eNOS degradation. These actions of
hyperglycemia may be mediated by oxidative stress, since
both peroxynitrite and nitrotyrosine may induce eNOS
degradation through UPS up-regulation [43]. Therefore,
ubiquitin-proteasome pathways are the major proteolytic
systems responsible for the regulated degradation of NOS
isozymes [44]. Based in large part on the finding that
eNOS degradation is blocked by lactacystin, MG132,
inhibitors of UPS activity, recent study [45] evidenced that
eNOS is primarily regulated by the proteasome pathway
in endothelial cells. These interactions, their functional
importance, and potential implication for vascular physi-
ology and pathophysiology need to further evidences.
However, the fact that eNOS is preferentially ubiquiti-
nated suggests that the loss of endothelial function during
hyperglycemia associated with a loss of eNOS activity may
be due to a combination of excessive oxidative stress and
UPS-dependent proteolysis [46].
Postprandial hyperglycemia effects on 
endothelial activation: role of UPS activity
Repeated exposure to postprandial hyperglycemia and
subsequently oxidative stress upregulation may contrib-
ute also the endothelial activation including the inflam-
matory and adhesive proprieties of endothelial cells
through UPS activation. Previous reports evidenced a role
for the UPS in the NFkB-dependent pro-inflammatory
cytokine production, particularly under conditions of
aggravated oxidative stress linked to hyperglycemia. In
muscle wasting, NFkB activation was noted in the pres-
ence of aggravated oxidative stress and UPS overactivity
[47]. Also, nitrotyrosine, which can be found in diabetic
atherosclerotic lesions, has been shown to activate NFkB
influencing UPS activity [48]. Various clinical studies sup-
port theevidence that an acute hyperglycemia during a
hyperglycemic clamp [49] or in the postprandial state [50]
can increase the production of plasma pro-inflammatory
cytokines. In the continuum of the events implicated in
the progression from endothelial dysfunction to endothe-
lial activation, the hyperglycemic effects on inflammation
have to be viewed together with those evidences that dem-
onstrated an increment of the adhesion molecules under
conditions of oxidative stress and UPS overactivity [51].
The UPS is involved in the internalization of the insulin  receptor, in the control of the amount of insulin receptor  substrates 1 and 2 Figure 3
The UPS is involved in the internalization of the insulin 
receptor, in the control of the amount of insulin receptor 
substrates 1 and 2.Cardiovascular Diabetology 2007, 6:35 http://www.cardiab.com/content/6/1/35
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Adhesion molecules regulate the interaction between
endothelium and leukocytes [52]. It is well known that
this is considered one of the earliest and reversible stages
of the process leading to atheromatous lesion. Among the
various proadhesive molecules, intracellular adhesion
molecule (ICAM)-1 has received particular interest.
Increase in the circulating form of this molecule has been
demonstrated in subjects with vascular disease [53] and
with diabetes, with or without vascular disease [54]. These
increases have been considered the indication of the acti-
vation of the atherogenic process. It has been demon-
strated that acute hyperglycemia in both normal and
diabetic subjects is a sufficient stimulus for the circulating
level of ICAM-1 to increase, thus activating one of the first
stages of the atherogenic process [55]. In addition to the
consideration of the UPS activity as being fairly impli-
cated on diabetic atherosclerosis, there are a number of
reports on the role of 20S proteasome-proteolytic activity
in regulation of adhesive properties of endothelium, for
instance the activation of UPS seems to be involved in the
upregulation of endothelial adhesion proteins VCAM-1
and ICAM-1 linked to oxidative stress increments [56].
Moreover, it has been shown that the protection provided
by the proteasome inhibitor MLN519 is related to an anti-
inflammatory effect linked with the modulation of NFkB
activity, attenuation of inflammatory cytokines and cellu-
lar adhesion molecule (ICAM-1 and E-selectin) expres-
sion into the endothelial cells [57]. This scenario supports
the concept that an increased UPS activity may be a mech-
anism linking glycemic oscillation with endothelial acti-
vation via an increased cytokine secretion as well as an
increased adhesion molecule production. This pathway
can lead the progression from endothelial activation,
already reversible alteration, toward endothelial damage
that may become irreversible alteration over time. Thus,
there is some initial evidence for a pathophysiologic role
of the UPS in the initial stage of atherogenesis in diabetes,
which may well be related to the NFkB activation path-
way.
Influence of overt diabetes on cardiovascular 
events: effect of UPS deregulation on plaque 
destabilization
In middle-aged patients, the seven-year incidence of myo-
cardial infarction among patients without diabetes who
had preexisting CHDwas similar to that among patients
with diabetes who did not have CHD, suggesting that type
2 diabetes may confer the same degree of risk as preexist-
ing CHD [58]. The issue of the association between diabe-
tes and CHD is likely to become more important, for two
reasons. First, the incidence of type 2 diabetes is increasing
among both high-risk populations and low-risk popula-
tions [59]. Second, although there has been a marked
decline in the rate of death due to CHD in the overall pop-
ulation over the past 35 years, this has not been the case
among persons with diabetes [60]. The reason for the dif-
ference is not known, but it may be that patients with dia-
betes have not benefited from reductions in risk factors for
cardiovascular disease. This possibility is clearly not the
explanation, since the reduction in the risk of CHD result-
ing from lipid reduction [61] and blood-pressurereduc-
tion [62] is similar for those with diabetes and those
without. Moreover, the standard multitargeted interven-
tion in the Steno-2 Studyshowed an event rate of the com-
bined cardiovascular end point of 7% per year [63].
Although the intensified intervention involving multiple
risk factors cut this event rate by half, it is still more than
three times as high as in the matched background popula-
tion, leaving muchroom for improvements. Thus, the dia-
betic status, independently from the classical
cardiovascular risk factors, may influence the atheroscle-
rotic plaque progression from stable to vulnerable, and so
toward a subject susceptible to an acute coronary syn-
drome or sudden cardiac death based on plaque rupture,
namely "cardiovascular vulnerable patients" [64]. In
recent years, it has been firmly established that inflamma-
tioncontributes to plaque rupture and cardiovascular
events [65]. However, little is known about the potentially
unique features of this inflammatory process in diabetes.
Several inflammatory markers have been identified in
atherosclerotic lesions. Among them are cytokines and
growth factors, which are released by activated macro-
phages that, together with T cells, are major cellular com-
ponents in atherosclerotic lesions [66]. Cytokines increase
the synthesis of platelet activating factor, stimulate lipoly-
sis, markedly stimulate the expression of adhesion mole-
cules, and upregulate the synthesis and cell surface
expression of procoagulant activity in endothelial cells.
Thus, cytokines may play a crucial role in the progression
of atherosclerotic lesions toward instability. However,
even if the inflammatory burden linked to diabetes not
only may lead to the initiation and progression of athero-
sclerosis but also may contribute to plaque rupture and
cardiovascular events, not much is known about inflam-
matory plaque differences as well as the plaque pheno-
type in subjects with versus those without diabetes. A thin
fibrous cap and a large lipid core in association with
inflammatory cell infiltration and necrotic areas, apopto-
sis of blood-borne and vascular cells, decrease in collagen
production, and increase in collagen degradation are key
characteristics of the unstable atheroma [67]. In atherec-
tomy specimens, the cell-rich and necrotic areas are
increased in de novo lesions in persons with diabetes [68].
In a series of coronary arteries examined after sudden
death, the extent of the necrotic core of plaques, calcifica-
tion, and healed ruptures were increased in patients with
type 2 diabetes [69]. Moreover, atherosclerotic lesions
from diabetic patients were characterized by higher apop-
tosis of VSMC, higher NFkB activation and MMP-9 levels
along with a lesser interstitialcollagen content [70]. So, allCardiovascular Diabetology 2007, 6:35 http://www.cardiab.com/content/6/1/35
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this might increase the risk of future acute ischemic events
precipitated by inflammatory-dependent rupture of
atherosclerotic plaques. The mechanisms linking inflam-
mation with plaque rupture in diabetes are not clear. It is
well recognizedthat inflammation is one manifestation of
oxidative stress [71] and the pathways that generate the
mediators of inflammation, such as adhesion molecules
and interleukins, are all induced by oxidative stress [72].
There are several studies demonstrating that patients with
diabetes not only have increased levels of circulating
markers of free radical-induced damage, but also have
reduced antioxidant defenses [73]. Although these proc-
esses can be potentiated by diabetes and can contribute to
the plaque rupture the molecular mechanisms linking
inflammation and oxidative stress with CHD in diabetic
plaques are not fully clarified. However, there is emerging
evidence about the potential role of UPS also in the evo-
lution of diabetic atherosclerotic plaques toward instabil-
ity, as evidenced by the observation that the ubiquitin-
proteasome pathway is required for activation of NFkB by
degradation of its inhibitory IkB proteins [74]. Thus, oxi-
dative stress the common factor underlying insulin-resist-
ance, type 2 diabetes mellitus and CHD, may explain the
presence of inflammation in all these conditions [75]. In
this context, recent data suggest an interesting mechanism
by which oxidative stress, increasing ubiquitin-proteas-
ome activity, may mediate inflammatory activity in dia-
betic atherosclerotic plaques. Macrophages, T-
lymphocytes and HDLA-DR+ inflammatory cells were
more abundant in diabetic than in nondiabetic plaques
and represented the major source of ubiquitin-proteas-
ome activity, suggesting the presence of an active inflam-
matory reaction in diabetic lesions [48]. Moreover, in
agreement with the difference in ubiquitin-proteasome
staining pattern, thehistological milieu of the lesions
appears different with regard to cellularity, but not in the
degree of vessel stenosis, suggesting that diabetic and
nondiabetic lesions are only different as regard to inflam-
matory burden. Of note, it has been shown that oxidative
stress can stimulate the UPS in macrophages by inducing
the expression of components of its enzymatic machinery
such as ubiquitin-binding proteins [19]. Accordingly, in
cultured monocytes from diabetic patients it has been evi-
denced that O2- production as well as ubiquitin-proteas-
ome activity and NFkB levels were significantly higher
when compared to nondiabetic patients [48]. Thus, it has
been proposed that increased ubiquitin-proteasome activ-
ity in plaque macrophage, as consequence of oxidative
stress overexpression, may enhance the synthesis of NFkB
in the same cell, possibly representing a crucial step in the
pathophysiology of diabetic plaque instability (Figure 2).
In line with this construct, the observations that the ubiq-
uitin-proteasome activity was greater in diabetic athero-
sclerotic lesions as compared to nondiabetic lesions, and
was associated with higher NFkB and MMP-9 levels along
with a lesser interstitial collagen content, suggest that this
system may have an important role in the inflammatory
process ofatherosclerotic plaques of type 2 diabetic
patients. However, the UPS upregulation may increases
the MMP-9 expression through NFkB activation, which is
known to regulate MMPs activity [76].
Therapeutic approach
The emerging studies, on the role of UPS in the initiation
and progression of atherosclerosis process, propose a
number of substances which readily penetrate the cell
membrane and inhibit the proteolytic function of the pro-
teasome complex [77]. So far, the majority of data relating
to the effects of proteasome inhibitors have been obtained
from cancer studies [78]. Initial reports on the effects of
proteasome inhibitors in cardiovascular diseases, how-
ever, indicate that proteasome inhibition might be an
effective therapeutic strategy for the reduction of the pro-
liferative phenomena of the progression stage of athero-
genesis [9]. Recent data on the improvement of
endothelium-dependent vasorelaxation in vitro, correlat-
ing with an increase in eNOS expression, suggest a thera-
peutic potential of proteasome inhibition in the early
stages of atherosclerosis [45]. Finally, these substances
exert a substantial anti-inflammatory effect, which was
attributed to a reduction in the activity of the factor NFkB
[9]. As the pathogenesis of cardiovascular events in dia-
betic patients involves the inflammation, the use of these
drugs may be an appealing therapy. In addition to the epi-
demiological evidence reviewed above for the role of
inflammation in diabetes-associated cardiovascular
events, clinical studies of patients on cardioprotective
drug regimens have revealed that many of the pharmaco-
therapies mediate their benefits, at least in part, through
anti-inflammatory activities. This is the case most strik-
ingly for one class of drugs that improves adipose tissue
physiology and insulin sensitivity, the peroxisome prolif-
erator-activated receptor-γ (PPARγ) agonists [79]. PPAR-γ
agonist rosiglitazone, reducing the inflammation, may
prevent plaque progression to an unstable phenotype in
diabetic patients with asymptomatic carotid stenosis,
enlisted to undergo carotid endarterectomy for extracra-
nial high-grade (>70%) internal carotid artery stenosis
[48]. The anti-inflammatory effects of glitazones are felt to
be mediated partly by their beneficial effects on glycemia,
but there is also evidence that glitazones may directly
modulate inflammation via transcription factors such as
NFKB [79]. In line with this construct, recent data show an
inhibitory effect of rosiglitazone on ubiquitin-proteasome
activity in diabetic lesions [48]. Indeed, at the same level
of blood glucose levels, diabetic patients treated with ros-
iglitazone had the lowest level of ubiquitin and proteas-
ome 20S activity, plaque inflammatory cells, cytokines,
oxidative stress and MMP-9 associated with the highest
content of plaque interstitial collagen. Thus, patientsCardiovascular Diabetology 2007, 6:35 http://www.cardiab.com/content/6/1/35
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assigned to rosiglitazone had lesser plaque progression to
an unstable phenotype compared with patients assigned
to placebo. Finally, it is worth noticing that for aspirin and
statins, two of the most successful drugs in cardiovascular
diseases, a proteasome inhibitory effect has been
described [80]. So, drugs that modulate the proteasomal
degradation of proteins could become novel agents for
the treatment of insulin-resistance and type 2 diabetes, as
well as the pharmacological therapies targeting UPS activ-
ity may be beneficial in the treatment of vascular biology
disorders associated with diabetes.
Conclusion
We have reviewed the impact of diabetes progression on
cardiovascular disease from endothelial dysfunction to
plaque destabilization. A puzzle of many pieces of evi-
dence suggests that UPS may be involved in the genera-
tion of insulin-resistance, diabetes, and cardiovascular
disease. The UPS is the main route of cellular protein deg-
radation. In addition to its role in the removal of damaged
proteins, the UPS is involved in a number of biological
processes including inflammation, proliferation, and
apoptosis. From what can be gathered from the very few
studies on the UPS in diabetic cardiovascular diseases
published so far, the system seems to be functionally
active to a different extent in the initiation, progression,
and complication stage of atherosclerosis in the diabetic
people. Further evidence for this theory, however, has to
be given, for instance by specifically targeted antagonism
of the UPS. Nonetheless, this hypothesis may help us
understand why diverse therapeutic interventions, which
have in common the ability to reduce ubiquitin-proteas-
ome activity, can impede or delay the onset of diabetes
and CVD. These early findings need further attention and
confirmation, importantly with regard to therapeutic
intervention, which would be indicated only if the system
was clearly found to be active and pathophysiologically
involved. New specific and causal inhibitors of proteas-
ome inhibitors are available and have been successfully
introduced as an adjunctive treatment option in cancer.
Whether this translates to the proliferative aspects of dia-
betic atherosclerosis remains to be cautiously awaited.
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